Cardiosense Appoints New CEO to Lead Growth of Wearable Heart Monitor

Cardiosense, a rising player in the wearable medical device industry, has announced the appointment of Eric Meizlish as its new CEO. This strategic move comes as the company seeks to capitalize on the recent 510(k) clearance of its CardioTag heart monitor and accelerate its growth in the competitive healthtech market.

Leadership Transition and Strategic Focus

Eric Meizlish, formerly the CEO of life science procurement platform Prendio-BioProcure, brings a wealth of experience in scaling healthtech companies. His appointment marks a significant shift in Cardiosense's leadership strategy, with co-founder Amit Gupta transitioning to the role of chief strategy officer.

Daniel Gottlieb, director at Cardiosense investor Broadview Ventures, emphasized the importance of this leadership change, stating, "Hiring a new CEO is an important step in the company's evolution as it scales its platform." Gottlieb expressed confidence in Meizlish's ability to accelerate Cardiosense's momentum in the market.

Product Development and Market Positioning

Cardiosense's flagship product, the CardioTag, received FDA 510(k) clearance in July 2025. This wearable device enables physicians to noninvasively monitor a patient's cardiac function, positioning the company at the forefront of remote patient monitoring technology.

The company is now focusing on two key areas:

1. Driving sales of the CardioTag heart monitor
2. Launching artificial intelligence models that pair with the device

These AI algorithms are being developed to interpret the wearable data, potentially offering more comprehensive and actionable insights for healthcare providers.

Strengthening the Leadership Team

In addition to Meizlish's appointment, Cardiosense has bolstered its executive ranks with the recent hiring of John Martin as chief medical officer. Martin, previously the chief medical officer emeritus at ultrasound company Butterfly Network, brings valuable cardiology expertise to Cardiosense's clinical development and product strategy efforts.

As a practicing vascular surgeon, Martin's clinical experience is expected to play a crucial role in refining Cardiosense's approach to cardiac monitoring and data interpretation.

With these strategic appointments and its recent FDA clearance, Cardiosense appears well-positioned to make significant strides in the wearable medical device market, potentially revolutionizing cardiac care through advanced monitoring and AI-driven insights.